Literature DB >> 27997080

Prevention of Allograft Rejection by Use of Regulatory T Cells With an MHC-Specific Chimeric Antigen Receptor.

F Noyan1,2, K Zimmermann1, M Hardtke-Wolenski1, A Knoefel3, E Schulde1, R Geffers4, M Hust5, J Huehn6, M Galla7, M Morgan7, A Jokuszies8, M P Manns1, E Jaeckel1,2.   

Abstract

CD4+ CD25high FOXP3+ regulatory T cells (Tregs) are involved in graft-specific tolerance after solid organ transplantation. However, adoptive transfer of polyspecific Tregs alone is insufficient to prevent graft rejection even in rodent models, indicating that graft-specific Tregs are required. We developed a highly specific chimeric antigen receptor that recognizes the HLA molecule A*02 (referred to as A2-CAR). Transduction into natural regulatory T cells (nTregs) changes the specificity of the nTregs without alteration of their regulatory phenotype and epigenetic stability. Activation of nTregs via the A2-CAR induced proliferation and enhanced the suppressor function of modified nTregs. Compared with nTregs, A2-CAR Tregs exhibited superior control of strong allospecific immune responses in vitro and in humanized mouse models. A2-CAR Tregs completely prevented rejection of allogeneic target cells and tissues in immune reconstituted humanized mice in the absence of any immunosuppression. Therefore, these modified cells have great potential for incorporation into clinical trials of Treg-supported weaning after allogeneic transplantation.
© 2016 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  T cell biology; basic (laboratory) research/science; gene therapy; immunobiology; immunosuppression/immune modulation; tissue (nonvascularized) transplantation; tolerance; tolerance: experimental; translational research/science

Mesh:

Substances:

Year:  2017        PMID: 27997080     DOI: 10.1111/ajt.14175

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  94 in total

Review 1.  Methods to manufacture regulatory T cells for cell therapy.

Authors:  K N MacDonald; J M Piret; M K Levings
Journal:  Clin Exp Immunol       Date:  2019-04-15       Impact factor: 4.330

Review 2.  Transplant trials with Tregs: perils and promises.

Authors:  Qizhi Tang; Flavio Vincenti
Journal:  J Clin Invest       Date:  2017-06-30       Impact factor: 14.808

Review 3.  Impact of infection on transplantation tolerance.

Authors:  Shuangjin Yu; Chang Su; Xunrong Luo
Journal:  Immunol Rev       Date:  2019-09-19       Impact factor: 12.988

4.  T cells expressing chimeric antigen receptor promote immune tolerance.

Authors:  Antonio Pierini; Bettina P Iliopoulou; Heshan Peiris; Magdiel Pérez-Cruz; Jeanette Baker; Katie Hsu; Xueying Gu; Ping-Ping Zheng; Tom Erkers; Sai-Wen Tang; William Strober; Maite Alvarez; Aaron Ring; Andrea Velardi; Robert S Negrin; Seung K Kim; Everett H Meyer
Journal:  JCI Insight       Date:  2017-10-19

Review 5.  Engineering therapeutic T cells to suppress alloimmune responses using TCRs, CARs, or BARs.

Authors:  Antoine Sicard; Megan K Levings; David W Scott
Journal:  Am J Transplant       Date:  2018-04-21       Impact factor: 8.086

6.  Regulatory T Cells for the Induction of Transplantation Tolerance.

Authors:  Weitao Que; Xiao-Kang Li
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

7.  Systematic testing and specificity mapping of alloantigen-specific chimeric antigen receptors in regulatory T cells.

Authors:  Nicholas Aj Dawson; Caroline Lamarche; Romy E Hoeppli; Peter Bergqvist; Vivian Cw Fung; Emma McIver; Qing Huang; Jana Gillies; Madeleine Speck; Paul C Orban; Jonathan W Bush; Majid Mojibian; Megan K Levings
Journal:  JCI Insight       Date:  2019-03-21

8.  Human CD8+ Tregs expressing a MHC-specific CAR display enhanced suppression of human skin rejection and GVHD in NSG mice.

Authors:  Séverine Bézie; Béatrice Charreau; Nadège Vimond; Juliette Lasselin; Nathalie Gérard; Véronique Nerrière-Daguin; Frédérique Bellier-Waast; Franck Duteille; Ignacio Anegon; Carole Guillonneau
Journal:  Blood Adv       Date:  2019-11-26

Review 9.  Dissecting the Tumor-Immune Landscape in Chimeric Antigen Receptor T-cell Therapy: Key Challenges and Opportunities for a Systems Immunology Approach.

Authors:  Gregory M Chen; Andrew Azzam; Yang-Yang Ding; David M Barrett; Stephan A Grupp; Kai Tan
Journal:  Clin Cancer Res       Date:  2020-03-03       Impact factor: 12.531

Review 10.  Immune monitoring as prerequisite for transplantation tolerance trials.

Authors:  K Behnam Sani; B Sawitzki
Journal:  Clin Exp Immunol       Date:  2017-06-23       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.